Autoinjectors Market

Autoinjectors Market by Usage (Reusable, Disposable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Anaphylaxis), Route of administration (SC, IM), Volume (<3ml, >3ml), End User (Home Care, Hospitals) - Global Forecast to 2028

Report Code: MD 6494 Jun, 2023, by marketsandmarkets.com

The global autoinjectors market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.7 billion by 2028, growing at a CAGR of 14.0% from 2023 to 2028.The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Where as, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. Autoinjectors offer advantages during medical emergency care as they can be administered by caregivers, family and patients themselves. Also, the market has observed growing number of regulatory approvals for devices as well as autoinjector finished formulations in last three years. These factors are expected to drive the market growth. Moreover, the loss of exclusivity of biologics and growing adoption rate of treatments given in home settings are the factors expected to offer opportunities for companies operating in this market. However, injectable route of administration is commonly accompanied with needle phobia. This is expected to limit the growth of autoinjectors adoption during the forecast period.

Attractive Opportunities in the Autoinjectors Market

Autoinjectors Devices Market

To know about the assumptions considered for the study, Request for Free Sample Report

Autoinjectors Devices Market Size

Autoinjectors Devices Market

Autoinjectors Market Dynamics

DRIVER: Benefits of autoinjectors in emergency medical care

Autoinjectors offer advantages including ease of administration, faster administration of medication. Conditions like anaphylactic shocks and opioid overdose require immediate medical assistance. Anaphylactic shocks are commonly caused due to food allergies, insect sting, drug allergies, among others and if not treated immediately, can be fatal. Epinephrine has always been considered as first line of treatment for anaphylaxis. The epinephrine autoinjectors offer advantages such as portability, quick administration and are beneficial for patients with the history of anaphylactic shocks. Therefore, autoinjectors play a vital role in the treatment of conditions demanding emergency medical care. These advantages offered by autoinjectors are expected to support the market growth.

RESTRAINT: Alternative modes of drug delivery such as oral, nasal among others and needle phobia

Conventionally injectable drugs have been administered using a syringe and is a painful mode of drug delivery. For this reason, the focus of healthcare professionals as well as patients is shifting to other modes of administration such as oral, nasal and topical routes. Moreover, technological advancements have also led to development of needle-free injectors as well. Moreover, the frequency of drug administration is high for diseases such as diabetes, rheumatoid arthritis, growth hormone deficiency among other conditions. Therefore, frequent injections might create needle phobia in patients of these conditions supporting the shift of these patients to other modes of drug administration.

OPPORTUNITY: Increasing shift of therapy to home settings

Home care settings are being increasingly focused on for several treatments globally. The factors that support this include advances in medical technology, large savings compared to treatments in hospital settings and evolving patient preferences among others. Moreover, the autoinjector market players are also shifting their focus on development of autoinjectors with technological advancements such as audio-visual cues for easy handling and administration, connectivity for better assistance,and large dose and volume devices for less frequent administration of drugs are collectively supporting the adoption of autoinjectors in home care setting, consequently offering opportunities in the market.

CHALLENGE: Development of autoinjectors for multiple drug viscosities

The viscosity of a drug affects various parameters of its administration.  Autoinjectors have the capability of delivering specific volume and viscosity of drugs auto specific speed of injection. The design of the autoinjector varies according to the viscosity of the drug. For instance, spring powered autoinjectors require springs with different physical features such as length thickness composition suitable to the viscosity of the drug to be administered. Therefore, one size fits all principal is not applicable to autoinjectors. Developing an auto injector suitable for different viscosities poses challenge of accommodating different injections speeds and volumes while ensuring of the safety and accuracy. Moreover, the performance of the autoinjector device can be impacted as a result of complex designing for different viscosities and volumes. However, despite these challenges, players in the market are focusing on innovation to develop autoinjectors that are compatible with a range of drug viscosities. Therefore, the impact of this challenge is expected to fade as the companies successfully develop new products to overcome this challenge.

Autoinjector Devices and Finished Formulations Market Ecosystem

Prominent companies in the market includes companies operating in the market for several years and posess diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in the autoinjectors market include Becton, Dickinson and Company (BD) (US), Ypsomed Holding AG (Switzerland), SHL Medical (Switzerland), West Pharmaceutical Services, Inc. (US), Recipharm AB (Sweden), Haselmeier GmbH (Germany), Owen Mumford Ltd. (UK), Philip-Medisize, LLC (US), Oval Medical Technologies Ltd. (UK), Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China), Antares Pharma, Inc. (US), and the some of the major market players for finished formulations include AbbVie Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (Switzerland), Merck KGaA (Germany), Viatris Inc. (US), and Biogen (US).

Autoinjectors Market Ecosystem

The disposable segment accounted for the largest share of the usage segment in overall autoinjectors market in 2023.

Autoinjectors are categorized as reusable and disposable based on their usage. In 2023, the usage segment accounted for the largest share of the autoinjectors devices and finished formulations market. This segment’s large share can primarily be attributed to factors such as features of manual autoinjectors including patient-centric design, ease of use, especially for patients with visual impairment, low dexterity.

The subcutaneous administration segment dominated the route of administration segment in overall autoinjectors market in 2023.

Based on the route of administration, the segment is categorized into subcutaneous and intramuscular. Manual autoinjectors accounted for the largest share of the market owing to the presence of large number of drugs administered subscutaneously and addition products being approved for this route of administration.

North America was the largest market for overall autoinjectors market in 2023.

Geographically, the overall market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The overall market is dominated by North America in 2023 and this dominance is anticipated to continue throughout the forecast period between 2023 and 2028. The region offers favorable reimbursement on use of autoinjectors. Also, growing number of cases of anaphylactic shock is likely to support adoption of autoinjectors. Additionally, the developed countries of the region have high level of awareness about self-administration drug delivery devices which is expected to further drive the market growth in the region.

Autoinjectors Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the autoinjectors market are Becton, Dickinson and Company (BD) (US), Ypsomed Holding AG (Switzerland), SHL Medical (Switzerland), West Pharmaceutical Services, Inc. (US), Recipharm AB (Sweden), Haselmeier GmbH (Germany), Owen Mumford Ltd. (UK), Gerreshiemer AG (Germany), Philip-Medisize, LLC (US), Oval Medical Technologies Ltd. (UK), Solteam Incorporation Co., Ltd. (China), Elcam Drug Delivery Devices (E3D) (Israel), Antares Pharma, Inc. (US), Jabil, Inc. (US), and the some of the major market players for finished formulations covered in this chapter include AbbVie Inc. (US), Amgen Inc. (US), Eli Lilly and Company (US), Novartis AG (Switzerland), Merck KGaA (Germany), Viatris Inc. (US), and Biogen (US).

Autoinjectors Market Report Scope

Report Metric 

Details 

Market Revenue in 2023

$0.9 billion

Projected Revenue by 2028

$1.7 billion

Revenue Rate

Poised to Grow at a CAGR of 14.0%

Market Driver

Benefits of autoinjectors in emergency medical care

Market Opportunity

Increasing shift of therapy to home settings

This report categorizes the Autoinjectors Market market to forecast revenue and analyze trends in each of the following submarkets:

By Usage

  • Disposable Autoinjectors
  • Reusable Autoinjectors

By Technology

  • Manual Autoinjectors
  • Automatic Autoinjectors

By Route of Administration

  • Subcutaneous
  • Intramuscular

By Type

  • Rheumatoid arthritis
  • Diabetes
  • Multiple Sclerosis
  • Anaphylaxis
  • Other therapy areas

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • India
    • China
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East and Africa

Recent Developments

  • In May 2023, SHL Medical and MoonLake Immunotherapeutics collaborated to develop the sonelokimab autoinjector. SHL Medical’s Molly autoinjector technology will be utilized for the clinical and potential commercial supply of MoonLake’s Nanobody sonelokimab.
  • In October 2022, BD partnered with Biocorp for Biocorp’s Injay technology, which adds connectivity to prefilled syringes. It is expected to aid BD in tracking adherence to self-administered injectable drugs.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 48)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
          FIGURE 1 AUTOINJECTORS MARKET SEGMENTATION
           1.3.1 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 54)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES 
          FIGURE 4 MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES
          FIGURE 5 MARKET SIZE ESTIMATION: OVERALL APPROACH
          FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: APPROACH 1 (REVENUE SHARE ANALYSIS)
    2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS 
          FIGURE 7 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
          FIGURE 8 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: APPROACH 1 (REVENUE SHARE ANALYSIS)
           2.3.1 INSIGHTS FROM PRIMARIES
                    FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
                    FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.4 GROWTH FORECAST 
          FIGURE 11 MARKET: CAGR PROJECTIONS
          FIGURE 12 AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS
          FIGURE 13 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 14 DATA TRIANGULATION METHODOLOGY
    2.6 RESEARCH ASSUMPTIONS 
    2.7 RISK ANALYSIS 
    2.8 IMPACT OF RECESSION ON MARKET 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
 
3 EXECUTIVE SUMMARY (Page No. - 68)
    FIGURE 15 AUTOINJECTORS MARKET, BY USAGE, 2023 VS. 2028 (USD MILLION)
    FIGURE 16 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2023 VS. 2028 (USD BILLION)
    FIGURE 17 MARKET, BY ROUTE OF ADMINISTRATION,  2023 VS. 2028 (USD MILLION)
    FIGURE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)
    FIGURE 19 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 20 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2023 VS. 2028 (USD BILLION)
    FIGURE 21 GEOGRAPHICAL SNAPSHOT: MARKET
    FIGURE 22 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR FINISHED FORMULATIONS MARKET
 
4 PREMIUM INSIGHTS (Page No. - 74)
    4.1 AUTOINJECTOR FINISHED FORMULATIONS AND DEVICES MARKET OVERVIEW 
          FIGURE 23 INCREASING NUMBER OF REGULATORY APPROVALS TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: AUTOINJECTORS MARKET SHARE,  BY USAGE AND COUNTRY (2022) 
          FIGURE 24 DISPOSABLE AUTOINJECTORS SEGMENT DOMINATED NORTH AMERICAN MARKET IN 2022
    4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND COUNTRY (2022) 
          FIGURE 25 SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR FINISHED FORMULATIONS MARKET IN 2022
    4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2023 VS. 2028 (USD MILLION) 
          FIGURE 26 RHEUMATOID ARTHRITIS SEGMENT TO CONTINUE TO DOMINATE  MARKET BY 2028
    4.5 OVERALL MARKET SHARE,  BY TECHNOLOGY, 2022 
          FIGURE 27 MANUAL AUTOINJECTORS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 28 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET FROM 2023 TO 2028
    4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET:  GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR FINISHED FORMULATIONS MARKET FROM 2023 TO 2028
 
5 MARKET OVERVIEW (Page No. - 79)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
FIGURE 30 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 2 MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Benefits of autoinjectors in emergency medical care
                    5.2.1.2 Increasing regulatory approvals for autoinjectors
                                TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE
                    5.2.1.3 Availability of generics and biosimilars in autoinjectors
                    5.2.1.4 Government support and favorable reimbursements
                    5.2.1.5 Growing awareness and adoption of self-administration
           5.2.2 RESTRAINTS
                    5.2.2.1 Alternative drug delivery modes and needle phobia
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Patent expiry of biologics
                                TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS
                    5.2.3.2 Increasing shift of therapy to home settings
           5.2.4 CHALLENGES
                    5.2.4.1 Development of autoinjectors for multiple drug viscosities
    5.3 KEY INDUSTRY TRENDS 
           5.3.1 INCREASING ADOPTION OF WEARABLE AUTOINJECTORS
           5.3.2 DEVELOPMENT AND LAUNCH OF ENVIRONMENT-FRIENDLY AUTOINJECTORS
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 31 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOINJECTOR PROVIDERS
    5.5 PRICING ANALYSIS 
          TABLE 5 AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 2020
          TABLE 6 INDICATIVE PRICING ANALYSIS OF AUTOINJECTOR FINISHED FORMULATIONS
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 32 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS
    5.7 SUPPLY CHAIN ANALYSIS 
          FIGURE 33 MARKET: SUPPLY CHAIN ANALYSIS
          TABLE 7 OVERALL SUPPLY CHAIN ECOSYSTEM FOR AUTOINJECTORS
    5.8 ECOSYSTEM ANALYSIS 
          FIGURE 34 ECOSYSTEM ANALYSIS: MARKET
    5.9 TECHNOLOGY ANALYSIS 
    5.10 PATENT ANALYSIS 
           FIGURE 35 PATENT APPLICATIONS FOR AUTOINJECTORS, JANUARY 2012–APRIL 2023
           TABLE 8 INDICATIVE LIST OF PATENTS IN MARKET
    5.11 KEY CONFERENCES AND EVENTS IN 2023–2024 
           TABLE 9 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.12 TRADE DATA 
           TABLE 10 IMPORT AND EXPORT DATA FOR PRODUCTS INCLUDING AUTOINJECTORS, AMONG OTHERS, 2022
    5.13 REGULATORY ANALYSIS 
           5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.14 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 15 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.14.1 THREAT OF NEW ENTRANTS
           5.14.2 THREAT OF SUBSTITUTES
           5.14.3 BARGAINING POWER OF SUPPLIERS
           5.14.4 BARGAINING POWER OF BUYERS
           5.14.5 INTENSITY OF COMPETITIVE RIVALRY
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTOR DEVICES
           5.15.2 BUYING CRITERIA FOR AUTOINJECTOR DEVICES
                     FIGURE 37 KEY BUYING CRITERIA FOR END USERS
 
6 AUTOINJECTORS MARKET, BY USAGE (Page No. - 103)
    6.1 INTRODUCTION 
          TABLE 16 MARKET, BY USAGE, 2021–2028 (USD MILLION)
          TABLE 17 MARKET, BY USAGE, 2021–2028 (MILLION UNITS)
          TABLE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
    6.2 DISPOSABLE AUTOINJECTORS 
           6.2.1 CONVENIENCE OF USE FOR PATIENTS TO DRIVE GROWTH
                    TABLE 19 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 20 MARKET, BY REGION,  2021–2028 (MILLION UNITS)
                    TABLE 21 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 22 EUROPE: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 23 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 24 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 25 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 27 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 REUSABLE AUTOINJECTORS 
           6.3.1 REUSABLE AUTOINJECTORS TO ACCOUNT FOR LOWER SHARE OF MARKET
                    TABLE 28 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 29 MARKET, BY REGION, 2021–2028 (MILLION UNITS)
                    TABLE 30 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 31 EUROPE: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 32 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 33 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 34 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 35 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 36 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
 
7 AUTOINJECTORS MARKET, BY TECHNOLOGY (Page No. - 113)
    7.1 INTRODUCTION 
          TABLE 37 AUTOINJECTORS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
          TABLE 38 MARKET, BY TECHNOLOGY, 2021–2028 (MILLION UNITS)
          TABLE 39 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
    7.2 MANUAL AUTOINJECTORS 
           7.2.1 MANUAL AUTOINJECTORS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE DURING FORECAST PERIOD
                    TABLE 40 MANUAL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 41 MANUAL MARKET, BY REGION, 2021–2028 (MILLION UNITS)
                    TABLE 42 NORTH AMERICA: MANUAL MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 43 EUROPE: MANUAL MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 44 ASIA PACIFIC: MANUAL MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 45 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 46 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 47 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 48 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 AUTOMATIC AUTOINJECTORS 
           7.3.1 AUTOMATIC AUTOINJECTORS INTEGRATE ELECTRONIC COMPONENTS AND ADDITIONAL FEATURES TO ENHANCE INJECTION PROCESS
                    TABLE 49 MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 50 MARKET, BY REGION, 2021–2028 (MILLION UNITS)
                    TABLE 51 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 52 EUROPE: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 53 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 54 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 55 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 56 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 57 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
 
8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 123)
    8.1 INTRODUCTION 
          TABLE 58 MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
          TABLE 59 MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (MILLION UNITS)
    8.2 SUBCUTANEOUS 
           8.2.1 INCREASING NUMBER OF PRODUCT APPROVALS TO DRIVE GROWTH
                    TABLE 60 MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 61 SUBCUTANEOUS MARKET, BY REGION,  2021–2028 (MILLION UNITS)
                    TABLE 62 NORTH AMERICA: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 EUROPE: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 INTRAMUSCULAR 
           8.3.1 INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES FASTER ABSORPTION OF MEDICATION
                    TABLE 65 MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 66 INTRAMUSCULAR MARKET, BY REGION,  2021–2028 (MILLION UNITS)
                    TABLE 67 NORTH AMERICA: MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 EUROPE: MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 ASIA PACIFIC: MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 AUTOINJECTORS MARKET, BY THERAPY AREA (Page No. - 130)
    9.1 INTRODUCTION 
          TABLE 70 MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
          TABLE 71 MARKET, BY THERAPY AREA, 2021–2028 (MILLION UNITS)
          TABLE 72 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
    9.2 RHEUMATOID ARTHRITIS 
           9.2.1 BENEFITS OF AUTOINJECTORS IN RHEUMATOID ARTHRITIS TREATMENT TO PROPEL GROWTH
                    TABLE 73 MARKET FOR RHEUMATOID ARTHRITIS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 74 MARKET FOR RHEUMATOID ARTHRITIS, BY REGION,  2021–2028 (MILLION UNITS)
                    TABLE 75 NORTH AMERICA: MARKET FOR RHEUMATOID ARTHRITIS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 76 EUROPE: MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 77 ASIA PACIFIC: MARKET FOR RHEUMATOID ARTHRITIS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS,  BY REGION, 2021–2028 (USD MILLION)
                    TABLE 79 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 DIABETES 
           9.3.1 LARGE DIABETIC POPULATION TO DRIVE DEMAND FOR AUTOINJECTORS
                    FIGURE 38 DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20–79 YEARS),  2019 VS. 2030 VS. 2045
                    TABLE 82 MARKET FOR DIABETES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 83 MARKET FOR DIABETES, BY REGION,  2021–2028 (MILLION UNITS)
                    TABLE 84 NORTH AMERICA: MARKET FOR DIABETES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 85 EUROPE: MARKET FOR DIABETES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 86 ASIA PACIFIC: MARKET FOR DIABETES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 87 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 88 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES,  BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 MULTIPLE SCLEROSIS 
           9.4.1 AVAILABILITY OF ORAL GENERIC MEDICINES TO NEGATIVELY IMPACT GROWTH
                    TABLE 91 MARKET FOR MULTIPLE SCLEROSIS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 92  MARKET FOR MULTIPLE SCLEROSIS, BY REGION,  2021–2028 (MILLION UNITS)
                    TABLE 93 NORTH AMERICA: MARKET FOR MULTIPLE SCLEROSIS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 94 EUROPE: MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 95 ASIA PACIFIC: MARKET FOR MULTIPLE SCLEROSIS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 96 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS,  BY REGION, 2021–2028 (USD MILLION)
                    TABLE 97 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 98 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 99 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
           9.4.2 ANAPHYLAXIS
                    9.4.2.1 Increasing prevalence of food allergies to drive growth
                                TABLE 100 MARKET FOR ANAPHYLAXIS, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 101 MARKET FOR ANAPHYLAXIS, BY REGION,  2021–2028 (MILLION UNITS)
                                TABLE 102 NORTH AMERICA: MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 103 EUROPE: MARKET FOR ANAPHYLAXIS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 104 ASIA PACIFIC: MARKET FOR ANAPHYLAXIS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 105 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 106 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 107 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 108 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS,  BY COUNTRY, 2021–2028 (USD MILLION)
           9.4.3 OTHER THERAPY AREAS
                    TABLE 109 MARKET FOR OTHER THERAPY AREAS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 110 MARKET FOR OTHER THERAPY AREAS, BY REGION,  2021–2028 (MILLION UNITS)
                    TABLE 111 NORTH AMERICA: MARKET FOR OTHER THERAPY AREAS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 112 EUROPE: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 113 ASIA PACIFIC: MARKET FOR OTHER THERAPY AREAS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 114 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 115 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 116 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 117 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 AUTOINJECTORS MARKET, BY VOLUME (Page No. - 153)
     10.1 INTRODUCTION 
             TABLE 118 MARKET, BY VOLUME, 2021–2028 (USD MILLION)
             TABLE 119 MARKET, BY VOLUME, 2021–2028 (MILLION UNITS)
     10.2 UP TO 3 ML VOLUME 
             10.2.1 INCREASING USE OF SUBCUTANEOUS INJECTIONS AGAINST CHRONIC DISEASES TO DRIVE GROWTH
                        TABLE 120 UP TO 3 ML VOLUME MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 121 UP TO 3 ML VOLUME MARKET, BY REGION,  2021–2028 (MILLION UNITS)
     10.3 ABOVE 3 ML VOLUME (LARGE VOLUME) 
             10.3.1 GROWING RESEARCH TO STUDY POTENTIAL OF LARGE-VOLUME AUTOINJECTORS TO DRIVE GROWTH
                        TABLE 122 ABOVE 3 ML VOLUME MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 123 ABOVE 3 ML VOLUME MARKET, BY REGION,  2021–2028 (MILLION UNITS)
 
11 AUTOINJECTORS MARKET, BY END USER (Page No. - 157)
     11.1 INTRODUCTION 
             TABLE 124 MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.2 HOME CARE SETTINGS 
             11.2.1 COST-EFFECTIVENESS OF HOME CARE THERAPIES TO PROPEL GROWTH
                        TABLE 125 MARKET FOR HOME CARE SETTINGS, BY REGION,  2021–2028 (USD MILLION)
                        TABLE 126 NORTH AMERICA: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 127 EUROPE: MARKET FOR HOME CARE SETTINGS, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 128 ASIA PACIFIC: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
     11.3 HOSPITALS AND CLINICS 
             11.3.1 USE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS AND CLINICS TO DRIVE GROWTH
                        TABLE 129 MARKET FOR HOSPITALS AND CLINICS, BY REGION,  2021–2028 (USD MILLION)
                        TABLE 130 NORTH AMERICA: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 131 EUROPE: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 132 ASIA PACIFIC: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
     11.4 AMBULATORY CARE SETTINGS 
             11.4.1 INCREASING PATIENT VOLUME IN AMBULATORY CARE SETTINGS TO DRIVE GROWTH
                        TABLE 133 MARKET FOR AMBULATORY CARE SETTINGS, BY REGION,  2021–2028 (USD MILLION)
                        TABLE 134 NORTH AMERICA: MARKET FOR AMBULATORY CARE SETTINGS,  BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 135 EUROPE: MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY,  2021–2028 (USD MILLION)
                        TABLE 136 ASIA PACIFIC: MARKET FOR AMBULATORY CARE SETTINGS,  BY COUNTRY, 2021–2028 (USD MILLION)
 
12 AUTOINJECTORS MARKET, BY REGION (Page No. - 165)
     12.1 INTRODUCTION 
             TABLE 137 MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 138 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION,  2021–2028 (USD MILLION)
     12.2 NORTH AMERICA 
             FIGURE 39 NORTH AMERICA: AUTOINJECTORS MARKET SNAPSHOT
             TABLE 139 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 140 NORTH AMERICA: MARKET, BY USAGE,  2021–2028 (USD MILLION)
             TABLE 141 NORTH AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 142 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
             TABLE 143 NORTH AMERICA: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
             TABLE 144 NORTH AMERICA: MARKET, BY VOLUME,  2021–2028 (USD MILLION)
             TABLE 145 NORTH AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             TABLE 146 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 147 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY USAGE, 2021–2028 (USD MILLION)
             TABLE 148 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 149 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
             TABLE 150 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
             TABLE 151 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
             TABLE 152 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.2.1 US
                        12.2.1.1 US to dominate North American market during forecast period
                                      TABLE 153 AUTOINJECTORS APPROVED BY US FDA, 2022
                                      TABLE 154 US: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 155 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 156 US: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 157 US: MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                                      TABLE 158 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 159 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 160 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 161 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 162 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 163 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.2.2 CANADA
                        12.2.2.1 Rising prevalence of chronic diseases to drive growth
                                      TABLE 164 CANADA: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 165 CANADA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 166 CANADA: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 167 CANADA: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 168 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 169 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 170 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 171 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 172 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 173 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.2.3 NORTH AMERICA: RECESSION IMPACT
     12.3 EUROPE 
             TABLE 174 EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 175 EUROPE: MARKET, BY USAGE, 2021–2028 (USD MILLION)
             TABLE 176 EUROPE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 177 EUROPE: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
             TABLE 178 EUROPE: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
             TABLE 179 EUROPE: MARKET, BY VOLUME, 2021–2028 (USD MILLION)
             TABLE 180 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             TABLE 181 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 182 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
             TABLE 183 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 184 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
             TABLE 185 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
             TABLE 186 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME,  2021–2028 (USD MILLION)
             TABLE 187 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.3.1 GERMANY
                        12.3.1.1 Growing government support to propel market
                                      TABLE 188 GERMANY: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 189 GERMANY: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 190 GERMANY: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 191 GERMANY: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 192 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 193 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 194 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 195 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 196 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                                      TABLE 197 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.3.2 UK
                        12.3.2.1 High prevalence of allergic conditions to boost growth
                                      TABLE 198 UK: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 199 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 200 UK: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 201 UK: MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                                      TABLE 202 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 203 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 204 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 205 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 206 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 207 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.3.3 FRANCE
                        12.3.3.1 Increasing prevalence of chronic diseases to support growth
                                      TABLE 208 FRANCE: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 209 FRANCE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 210 FRANCE: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 211 FRANCE: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 212 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 213 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 214 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 215 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 216 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 217 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.3.4 ITALY
                        12.3.4.1 Rising prevalence of chronic diseases to propel growth
                                      TABLE 218 ITALY: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 219 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 220 ITALY: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 221 ITALY: MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                                      TABLE 222 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 223 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 224 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 225 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 226 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 227 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.3.5 SPAIN
                        12.3.5.1 Favorable reimbursement scenario to support growth
                                      TABLE 228 SPAIN: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 229 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 230 SPAIN: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 231 SPAIN: MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                                      TABLE 232 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 233 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 234 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 235 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 236 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 237 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.3.6 REST OF EUROPE
                        TABLE 238 REST OF EUROPE: AUTOINJECTORS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                        TABLE 239 REST OF EUROPE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 240 REST OF EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 241 REST OF EUROPE: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                        TABLE 242 REST OF EUROPE: MARKET, BY END USER,  2021–2028 (USD MILLION)
                        TABLE 243 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY USAGE, 2021–2028 (USD MILLION)
                        TABLE 244 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 245 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 246 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                        TABLE 247 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.7 EUROPE: RECESSION IMPACT
     12.4 ASIA PACIFIC 
             FIGURE 40 ASIA PACIFIC: AUTOINJECTORS MARKET SNAPSHOT
             TABLE 248 ASIA PACIFIC: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 249 ASIA PACIFIC: MARKET, BY USAGE, 2021–2028 (USD MILLION)
             TABLE 250 ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 251 ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
             TABLE 252 ASIA PACIFIC: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
             TABLE 253 ASIA PACIFIC: MARKET, BY VOLUME,  2021–2028 (USD MILLION)
             TABLE 254 ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
             TABLE 255 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 256 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
             TABLE 257 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 258 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
             TABLE 259 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
             TABLE 260 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
             TABLE 261 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.4.1 JAPAN
                        12.4.1.1 Presence of large geriatric population to boost growth
                                      TABLE 262 JAPAN: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 263 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 264 JAPAN: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 265 JAPAN: MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                                      TABLE 266 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 267 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 268 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 269 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 270 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 271 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.4.2 CHINA
                        12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to drive growth
                                      TABLE 272 CHINA: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 273 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 274 CHINA: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 275 CHINA: MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                                      TABLE 276 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 277 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 278 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 279 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 280 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 281 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.4.3 INDIA
                        12.4.3.1 Increasing burden of diabetes and CVD to drive growth
                                      TABLE 282 INDIA: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 283 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 284 INDIA: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 285 INDIA: MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                                      TABLE 286 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                                      TABLE 287 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 288 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 289 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 290 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 291 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY END USER, 2021–2028 (USD MILLION)
             12.4.4 SOUTH KOREA
                        12.4.4.1 Regulatory approvals for autoinjectors to drive growth
                                      TABLE 292 SOUTH KOREA: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                                      TABLE 293 SOUTH KOREA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 294 SOUTH KOREA: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                                      TABLE 295 SOUTH KOREA: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                                      TABLE 296 SOUTH KOREA: MARKET, BY END USER,  2021–2028 (USD MILLION)
                                      TABLE 297 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                                      TABLE 298 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 299 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                                      TABLE 300 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                                      TABLE 301 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY END USER, 2021–2028 (USD MILLION)
             12.4.5 REST OF ASIA PACIFIC
                        TABLE 302 ROAPAC: AUTOINJECTORS MARKET, BY USAGE, 2021–2028 (USD MILLION)
                        TABLE 303 ROAPAC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 304 ROAPAC: MARKET, BY ROUTE OF ADMINISTRATION,  2021–2028 (USD MILLION)
                        TABLE 305 ROAPAC: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                        TABLE 306 ROAPAC: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 307 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                        TABLE 308 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 309 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 310 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                        TABLE 311 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER,  2021–2028 (USD MILLION)
             12.4.6 ASIA PACIFIC: RECESSION IMPACT
     12.5 LATIN AMERICA 
             12.5.1 RISING GERIATRIC POPULATION TO SUPPORT GROWTH
                        TABLE 312 LATIN AMERICA: AUTOINJECTORS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                        TABLE 313 LATIN AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 314 LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 315 LATIN AMERICA: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                        TABLE 316 LATIN AMERICA: MARKET, BY VOLUME,  2021–2028 (USD MILLION)
                        TABLE 317 LATIN AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
                        TABLE 318 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY USAGE, 2021–2028 (USD MILLION)
                        TABLE 319 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 320 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 321 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                        TABLE 322 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME,  2021–2028 (USD MILLION)
                        TABLE 323 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.2 LATIN AMERICA: RECESSION IMPACT
     12.6 MIDDLE EAST & AFRICA 
             12.6.1 FAVORABLE REFORMS IN AFRICA AND MIDDLE EASTERN COUNTRIES TO DRIVE GROWTH
                        TABLE 324 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USAGE,  2021–2028 (USD MILLION)
                        TABLE 325 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 326 MIDDLE EAST & AFRICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 327 MIDDLE EAST & AFRICA: MARKET, BY THERAPY AREA,  2021–2028 (USD MILLION)
                        TABLE 328 MIDDLE EAST & AFRICA: MARKET, BY VOLUME,  2021–2028 (USD MILLION)
                        TABLE 329 MIDDLE EAST & AFRICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
                        TABLE 330 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY USAGE, 2021–2028 (USD MILLION)
                        TABLE 331 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 332 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
                        TABLE 333 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
                        TABLE 334 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
                        TABLE 335 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET,  BY END USER, 2021–2028 (USD MILLION)
             12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

13 COMPETITIVE LANDSCAPE (Page No. - 244)
     13.1 INTRODUCTION 
     13.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 41 AUTOINJECTOR DEVICES AND FINISHED FORMULATIONS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     13.3 REVENUE SHARE ANALYSIS FOR AUTOINJECTORS MARKET 
             FIGURE 42 AUTOINJECTORS MARKET: REVENUE ANALYSIS OF KEY PLAYERS,  2020–2022
     13.4 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET 
             FIGURE 43 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
     13.5 MARKET SHARE ANALYSIS FOR AUTOINJECTORS MARKET 
             FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET, 2022
             TABLE 336 AUTOINJECTORS MARKET: DEGREE OF COMPETITION
     13.6 MARKET SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET 
             FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET, 2022
             TABLE 337 AUTOINJECTOR FINISHED FORMULATIONS MARKET: DEGREE OF COMPETITION
     13.7 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 
             FIGURE 46 AUTOINJECTORS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
             13.7.1 STARS
             13.7.2 EMERGING LEADERS
             13.7.3 PERVASIVE PLAYERS
             13.7.4 PARTICIPANTS
     13.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 
             13.8.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 338 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
             13.8.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 339 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
     13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES 
             FIGURE 47 AUTOINJECTORS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
             13.9.1 PROGRESSIVE COMPANIES
             13.9.2 STARTING BLOCKS
             13.9.3 RESPONSIVE COMPANIES
             13.9.4 DYNAMIC COMPANIES
     13.10 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 
             TABLE 340 AUTOINJECTORS MARKET: LIST OF KEY STARTUP/SME PLAYERS
             TABLE 341 AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
     13.11 COMPETITIVE SCENARIO AND TRENDS 
             13.11.1 PRODUCT LAUNCHES
                        TABLE 342 AUTOINJECTORS MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023
             13.11.2 DEALS
                        TABLE 343 AUTOINJECTORS MARKET: DEALS, JANUARY 2020–APRIL 2023
             13.11.3 OTHER DEVELOPMENTS
                        TABLE 344 AUTOINJECTORS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023
             13.11.4 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
                        TABLE 345 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
             13.11.5 DEVICES FOR LARGE-VOLUME FORMULATIONS
                        TABLE 346 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS
             13.11.6 DEVICES FOR HIGHLY VISCOUS FORMULATIONS
                        TABLE 347 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS
                        TABLE 348 FORMULATIONS AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS
             13.11.7 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET
 
14 COMPANY PROFILES (Page No. - 264)
     14.1 KEY PLAYERS: DEVICES 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             14.1.1 BECTON, DICKINSON AND COMPANY (BD)
                        TABLE 349 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
                        FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
                        TABLE 350 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS
                        TABLE 351 BECTON, DICKINSON AND COMPANY: DEALS
                        TABLE 352 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS
             14.1.2 YPSOMED HOLDING AG
                        TABLE 353 YPSOMED HOLDING AG: COMPANY OVERVIEW
                        FIGURE 49 YPSOMED HOLDING AG: COMPANY SNAPSHOT
                        TABLE 354 YPSOMED HOLDING AG: PRODUCT OFFERINGS
                        TABLE 355 YPSOMED HOLDING AG: PRODUCT LAUNCHES
                        TABLE 356 YPSOMED HOLDING AG: DEALS
             14.1.3 SHL MEDICAL
                        TABLE 357 SHL MEDICAL: COMPANY OVERVIEW
                        TABLE 358 SHL MEDICAL: PRODUCT OFFERINGS
                        TABLE 359 SHL MEDICAL: DEALS
                        TABLE 360 SHL MEDICAL: OTHER DEVELOPMENTS
             14.1.4 WEST PHARMACEUTICAL SERVICES, INC.
                        TABLE 361 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
                        FIGURE 50 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 362 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT OFFERINGS
                        TABLE 363 WEST PHARMACEUTICAL SERVICES, INC.: OTHER DEVELOPMENTS
             14.1.5 RECIPHARM AB
                        TABLE 364 RECIPHARM AB: COMPANY OVERVIEW
                        TABLE 365 RECIPHARM AB: PRODUCT OFFERINGS
                        TABLE 366 RECIPHARM AB: DEALS
             14.1.6 HASELMEIER GMBH
                        TABLE 367 HASELMEIER GMBH: COMPANY OVERVIEW
                        TABLE 368 HASELMEIER GMBH: PRODUCT OFFERINGS
                        TABLE 369 HASELMEIER GMBH: DEALS
                        TABLE 370 HASELMEIER GMBH: PRODUCT LAUNCHES
             14.1.7 OWEN MUMFORD LTD.
                        TABLE 371 OWEN MUMFORD LTD.: COMPANY OVERVIEW
                        TABLE 372 OWEN MUMFORD LTD.: PRODUCT OFFERINGS
                        TABLE 373 OWEN MUMFORD LTD.: PRODUCT LAUNCHES
                        TABLE 374 OWEN MUMFORD LTD.: DEALS
                        TABLE 375 OWEN MUMFORD LTD.: OTHER DEVELOPMENTS
             14.1.8 GERRESHEIMER AG
                        TABLE 376 GERRESHEIMER AG: COMPANY OVERVIEW
                        FIGURE 51 GERRESHEIMER AG: COMPANY SNAPSHOT (2022)
                        TABLE 377 GERRESHEIMER AG: PRODUCT OFFERINGS
                        TABLE 378 GERRESHEIMER AG: DEALS
             14.1.9 PHILLIPS-MEDISIZE, LLC
                        TABLE 379 PHILIPS-MEDISIZE, LLC: COMPANY OVERVIEW
                        TABLE 380 PHILIPS MEDISIZE, LLC: PRODUCT OFFERINGS
                        TABLE 381 PHILIPS MEDISIZE, LLC: PRODUCT LAUNCHES
                        TABLE 382 PHILIPS-MEDISIZE, LLC: OTHER DEVELOPMENTS
             14.1.10 OVAL MEDICAL TECHNOLOGIES LTD. (PART OF SMC LTD.)
                        TABLE 383 OVAL MEDICAL TECHNOLOGIES LTD.: COMPANY OVERVIEW
                        TABLE 384 OVAL MEDICAL TECHNOLOGIES LTD.: PRODUCT OFFERINGS
             14.1.11 KALEO, INC.
                        TABLE 385 KALEO, INC.: COMPANY OVERVIEW
                        TABLE 386 KALEO, INC.: PRODUCT OFFERINGS
             14.1.12 SOLTEAM INCORPORATION CO., LTD.
                        TABLE 387 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW
                        TABLE 388 SOLTEAM INCORPORATION CO., LTD.: PRODUCT OFFERINGS
             14.1.13 ELCAM DRUG DELIVERY DEVICES (E3D)
             14.1.14 CROSSJECT
                        TABLE 391 CROSSJECT: COMPANY OVERVIEW
                        TABLE 392 CROSSJECT: PRODUCT OFFERINGS
             14.1.15 JOHNSON MEDTECH, LLC.  (PART OF JOHNSON ELECTRIC HOLDINGS LTD.)
                        TABLE 393 JOHNSON MEDTECH, LLC.: COMPANY OVERVIEW
                        TABLE 394 JOHNSON MEDTECH, LLC: PRODUCT OFFERINGS
             14.1.16 ANTARES PHARMA, INC. (PART OF HALOZYME, INC.)
                        TABLE 395 ANTARES PHARMA, INC.: COMPANY OVERVIEW
                        FIGURE 52 ANTARES PHARMA, INC.: COMPANY SNAPSHOT
                        TABLE 396 ANTARES PHARMA, INC.: PRODUCT OFFERINGS
                        TABLE 397 ANTARES PHARMA, INC.: DEALS
             14.1.17 JABIL, INC.
                        TABLE 398 JABIL, INC.: COMPANY OVERVIEW
                        TABLE 399 JABIL INC.: PRODUCT OFFERINGS
             14.1.18 CONGRUENCE MEDICAL SOLUTIONS LLC
                        TABLE 400 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW
                        TABLE 401 CONGRUENCE MEDICAL SOLUTIONS LLC: PRODUCT OFFERINGS
     14.2 KEY PLAYERS: FINISHED FORMULATIONS 
             14.2.1 ABBVIE INC.
                        TABLE 402 ABBVIE INC.: COMPANY OVERVIEW
                        FIGURE 53 ABBVIE INC.: COMPANY SNAPSHOT
                        TABLE 403 ABBVIE INC.: PRODUCT OFFERINGS
                        TABLE 404 ABBVIE INC.: PRODUCT LAUNCHES
                        TABLE 405 ABBVIE INC.: OTHER DEVELOPMENTS
             14.2.2 AMGEN INC.
                        TABLE 406 AMGEN INC.: COMPANY OVERVIEW
                        FIGURE 54 AMGEN INC.: COMPANY SNAPSHOT
                        TABLE 407 AMGEN INC.: PRODUCT OFFERINGS
                        TABLE 408 AMGEN INC.: PRODUCT LAUNCHES
             14.2.3 ELI LILLY AND COMPANY
                        TABLE 409 ELI LILY AND COMPANY: COMPANY OVERVIEW
                        FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
                        TABLE 410 ELI LILY AND COMPANY: PRODUCT OFFERINGS
                        TABLE 411 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
             14.2.4 NOVARTIS AG
                        TABLE 412 NOVARTIS AG: COMPANY OVERVIEW
                        FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT
                        TABLE 413 NOVARTIS AG: PRODUCT OFFERINGS
                        TABLE 414 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS
             14.2.5 MERCK KGAA
                        TABLE 415 MERCK KGAA: COMPANY OVERVIEW
                        FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT
                        TABLE 416 MERCK KGAA: PRODUCT OFFERINGS
             14.2.6 VIATRIS INC. (FORMERLY MYLAN INC.)
                        TABLE 417 VIATRIS INC.: COMPANY OVERVIEW
                        FIGURE 58 VIATRIS INC.: COMPANY SNAPSHOT
                        TABLE 418 VIATRIS INC.: PRODUCT OFFERINGS
             14.2.7 BIOGEN
                        TABLE 419 BIOGEN: COMPANY OVERVIEW
                        FIGURE 59 BIOGEN: COMPANY SNAPSHOT
                        TABLE 420 BIOGEN: PRODUCT OFFERINGS
                        TABLE 421 BIOGEN: OTHER DEVELOPMENTS
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
15 APPENDIX (Page No. - 320)
     15.1 DISCUSSION GUIDE 
     15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     15.3 CUSTOMIZATION OPTIONS 
     15.4 RELATED REPORTS 
     15.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the autoinjectors market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the autoinjectors market. The secondary sources used for this study include some of the key secondary sources referred to for this study include publications from government sources government sources, such as the World Health Organization (WHO), National Institutes of Health (NIH), World Bank, United States Food and Drug Administration (US FDA), India Brand Equity Foundation (IBEF), ScienceDirect, and Eurostat, among others. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global autoinjectors market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Autoinjectors Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the autoinjectors market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the autoinjectors business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources  

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Autoinjectors are easy-to-handle and cost-effective medical devices that deliver a pre-measured dose of medication and can be used by patients for the self-administration of drugs. They can also be used by caregivers and untrained personnel to deliver a dose of the required drug. Patients use autoinjectors mainly to manage autoimmune and chronic diseases.

Key Stakeholders

  • Companies manufacturing autoinjectors
  • Original equipment manufacturing companies
  • Suppliers and distributors of autoinjectors
  • Healthcare service providers
  • Health insurance payers
  • Government bodies/municipal corporations
  • Regulatory bodies
  • Medical research institutes
  • Business research and consulting service providers
  • Venture capitalists
  • Market research and consulting firms

Report Objectives

  • To define, describe, analyze, and forecast the autoinjectors market by usage, technology, therapy area, volume, route of administration, end user, and region
  • To provide detailed information about the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall autoinjectors market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their market shares and core competencies2 in the autoinjectors market
  • To track and analyze competitive developments such as partnerships, collaborations, agreements, acquisitions, product launches, and expansions in the autoinjectors market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • Twenty five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 6494
Published ON
Jun, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Autoinjectors Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback